AEMD Company Profile and Key Details

AEMD has shown mixed momentum, gaining 13.45% over the past week and -50.29% over the past quarter, though year-to-date performance is down -2.53%. Short-term trend indicators are bullishly aligned (SMA20 -7.25%, SMA50 -20.39%, SMA200 -79.69%). The stock’s 14-day RSI is 36.43 (weak momentum), while the ATR of 0.2 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -95.83% below its high and over 7.67% above its low. Average 10-day trading volume of 189.27 thousand shares is significantly above the 3-month average of 65.32 thousand, indicating heightened recent market interest.

Aethlon Medical, Inc. generated EPS of -$45.83 over the past year. Five-year average earnings growth is 43.53%. Wall Street analysts project EPS growth of 82.0% annually over the next five years. The latest quarter delivered EPS of -$3.74. The next quarter is forecast at -$2.01. Next year's EPS is expected at -$5.78. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $1.50 to $1.50. The high target offers -32.43% upside. The low target suggests -32.43% downside. The mean target is $1.50. This offers -32.43% upside. Aethlon Medical, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 120.0%. The prior quarter beat by 25.0%. Over the last six quarters, Apple has recorded several small beats. These include -22.73% in August 14, 2024.

Aethlon Medical, Inc. has 1.32 million shares outstanding. The public float is 1.22 million shares, elevated short interest at 5.43% of float. This equals 71.04 thousand shares. The short ratio is 1.19 days. Institutional investors hold 4.94% of the float. Insiders own 1.9%. BROENNIMAN EDWARD G holds 282.17 thousand shares, BARRY FRANKLYN S JR has 106.59 thousand shares and Shah Chetan has 16.64 thousand shares.

Aethlon Medical, Inc. (NASDAQ:AEMD) closed at $2.22 USD, gaining $0.11 (5.21%) from the previous close of $2.11. The stock is currently mid-range between its 52-week high and low $1.36 and $35.20. With a market capitalization of about $1.69 million, Aethlon Medical, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.65). Key stats such as the average daily volume over the past year has been around 64.32 thousand shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Aethlon Medical, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO James Frakes, the company employs approximately 14 people and listed since March 04, 1999. Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States.

Aethlon Medical, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.11. This means the shares are trading below this model’s fair value.

Aethlon Medical, Inc. trades at a P/E ratio of -0.16, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.27 suggesting the stock is closer to book value. The P/FCF stands at -0.0, also below market averages.

Our AI price prediction model suggests that Aethlon Medical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -11.71%, with price expected at $1.96 by March 31, 2026, within a range of $1.80 to $2.13 3-Month Outlook: Projected fall of -55.41%, reaching $0.99 by June 15, 2026, with a range of $0.46 to $1.56. 1-Year Outlook: Projected loss of -93.69%, with price at $0.14 by March 17, 2027, within a range of $0.00 to $0.65.

Aethlon Medical, Inc. (NASDAQ:AEMD) shares are flat -2.53% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Aethlon Medical, Inc. trading at a premium to the broader market with a P/E of -0.16. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $5.43, suggesting 144.59% upside. Our AI forecast model points to short-term weakness (-11.71% over two weeks), a medium-term fall (-55.41% over three months), and a longer-term loss (-93.69% over one year), with expected trading ranges indicating moderate volatility.